Geode Capital Management’s Melinta Therapeutics MLNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
– Sell
-113,002
Closed -$60K – 4278
2019
Q4
$60K Sell
113,002
-31,761
-22% -$77K ﹤0.01% 4065
2019
Q3
$551K Sell
144,763
-1,886
-1% -$6.79K ﹤0.01% 3444
2019
Q2
$975K Buy
146,649
+23,267
+19% +$88.6K ﹤0.01% 3246
2019
Q1
$438K Buy
123,382
+39,631
+47% +$215K ﹤0.01% 3484
2018
Q4
$331K Buy
83,751
+2,668
+3% +$34.1K ﹤0.01% 3519
2018
Q3
$1.6M Buy
81,083
+11,253
+16% +$284K ﹤0.01% 3005
2018
Q2
$2.22M Buy
69,830
+41,865
+150% +$1.51M ﹤0.01% 2797
2018
Q1
$1.03M Buy
27,965
+11,853
+74% +$779K ﹤0.01% 3104
2017
Q4
$1.27M Buy
+16,112
New +$1.19M ﹤0.01% 3004

Geode Capital Management's MLNT Position: Q1 2020 in Review

Geode Capital Management sold out of Melinta Therapeutics (MLNT) in Q1 2020, closing a stake of 113,002 shares — an estimated $60K sold.

Geode Capital Management first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $2.22M in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

  • Geode Capital Management reported no remaining Melinta Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Geode Capital Management sold 113,002 Melinta Therapeutics shares in Q1 2020, an estimated $60K.
  • Geode Capital Management first reported a position in Melinta Therapeutics in Q4 2017 and held it in 9 quarters.
  • Geode Capital Management's Melinta Therapeutics position peaked at $2.22M in Q2 2018.
  • 2 funds tracked by Wall St. Rank held Melinta Therapeutics as of Q1 2020.

Based on Geode Capital Management's 13F filing for Q1 2020, filed 14 May 2020.